Indication
Metastatic hormone-sensitive prostate cancer
5 clinical trials
7 products
2 drugs
Product
DarolutamideClinical trial
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean PatientsStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Product
BAY1841788Product
Standard ADTClinical trial
A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate CancerStatus: Completed, Estimated PCD: 2021-10-25
Clinical trial
Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control ArmStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Product
DocetaxelProduct
PlaceboClinical trial
CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2013-12-23
Product
Androgen-Deprivation TherapyDrug
docetaxelClinical trial
Prospective, Multi-Country, Observational Study of Clinical Outcomes for Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With ADT Plus Apalutamide or Enzalutamide Under Routine Clinical Practice (ArtemisPRO)Status: Recruiting, Estimated PCD: 2025-09-05
Product
ApalutamideDrug
enzalutamide